April 25, 2017 4:58 AM ET

Healthcare Equipment and Supplies

Company Overview of Tandem Diabetes Care, Inc.

Company Overview

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system. In addition, the company offers Tandem Device Updater, a PC and Mac-compatible Web-based system that allows users to update their pump’s so...

11045 Roselle Street

San Diego, CA 92121

United States

Founded in 2006

591 Employees

Phone:

858-366-6900

Key Executives for Tandem Diabetes Care, Inc.

Chief Executive Officer, President and Director
Age: 64
Total Annual Compensation: $569.0K
Chief Financial Officer, Executive Vice President and Treasurer
Age: 50
Total Annual Compensation: $474.5K
Chief Operating Officer and Executive Vice President
Age: 61
Total Annual Compensation: $474.5K
Chief Commercial Officer and Executive Vice President
Age: 48
Total Annual Compensation: $431.3K
Compensation as of Fiscal Year 2016.

Tandem Diabetes Care, Inc. Key Developments

Tandem Diabetes Care, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2016; Provides Sales Guidance for the First Quarter of 2017; Provides Earnings Guidance for the Year Ending December 31, 2017

Tandem Diabetes Care, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2016. For the quarter, the company reported sales of $28,912,000 against $29,120,000 a year ago. Operating loss was $13,346,000 against $11,221,000 a year ago. Loss before taxes was $14,837,000 against $12,083,000 a year ago. Net loss was $14,822,000 or $0.48 per share basic and diluted against $12,093,000 or $0.40 per share basic and diluted a year ago. For the year, the company reported sales of $84,248,000 against $72,850,000 a year ago. Operating loss was $78,051,000 against $69,004,000 a year ago. Loss before taxes was $83,462,000 against $72,408,000 a year ago. Net loss was $83,447,000 or $2.73 per share basic and diluted against $72,418,000 or $2.50 per share basic and diluted a year ago. For the year ending December 31, 2017, the company expects non-GAAP sales are estimated to be in the range of $100 million to $107 million. Non-GAAP operating margin is estimated to be in the range of negative 70% to negative 65%, For the first quarter, the company expects non-GAAP sales for the first quarter 2017 are estimated to be 15% of annual sales.

Tandem Diabetes Care, Inc. Auditor Raises 'Going Concern' Doubt

Tandem Diabetes Care, Inc. filed its 10-K on Mar 08, 2017 for the period ending Dec 31, 2016. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Tandem Diabetes Care, Inc. Launches Remote Software Update for Insulin Pump Using a Personal Computer

Tandem Diabetes Care, Inc. announced the release of a software update for t:slim Insulin Pumps purchased before April 2015. The software update will be available via personal computer using the Tandem Device Updater, a Mac® and PC-compatible tool for the remote deployment of Tandem insulin pump software. This represents the first time an insulin pump manufacturer has provided a software update for customers using their personal computer. The features included in this software release began shipping on new t:slim Pumps in April 2015, and include a variety of product enhancements for convenience and flexibility. Consistent with past product development efforts, the design of the Tandem Device Updater was driven significantly by direct input from pump users. Following clearance by the U.S. Food and Drug Administration, Tandem conducted additional customer testing to further refine the user experience. Approximately two thirds of the 300 customers who participated in the beta release completed a survey after their download. Survey results reported that the product was easy to use, with more than 90% indicating they would be likely to download future software updates.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tandem Diabetes Care, Inc., please visit www.tandemdiabetes.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.